Literature DB >> 18769255

Recent advances in distal myopathy with rimmed vacuoles (DMRV) or hIBM: treatment perspectives.

May Christine V Malicdan1, Satoru Noguchi, Ichizo Nishino.   

Abstract

PURPOSE OF REVIEW: Distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy is an adult-onset autosomal recessive, slowly progressive and debilitating myopathy due to mutations in the gene that regulates the synthesis of sialic acid. This review aims to update our knowledge of this myopathy and to review studies about pathomechanism and therapeutic strategies. RECENT
FINDINGS: Owing to the mutated gene, it was expected that the pathomechanism of this myopathy would be based on hyposialylation, a highly controversial phenomenon. This concept has been supported by findings in two recently generated animal models. In addition, the intracellular amyloid-beta accumulation in a distal myopathy with rimmed vacuole mouse model is relevant to similar findings in patients.
SUMMARY: Clarifying the role of hyposialylation in distal myopathy with rimmed vacuole/hereditary inclusion body myopathy could potentially lead to a therapeutic strategy for this progressive myopathy. In addition, strategies aimed at preventing amyloid-beta deposition or enhancing its clearance could also be beneficial, as this epiphenomenon is now known to occur early in the course of the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18769255     DOI: 10.1097/WCO.0b013e32830dd595

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  9 in total

1.  Activation of the Unfolded Protein Response in Sporadic Inclusion-Body Myositis but Not in Hereditary GNE Inclusion-Body Myopathy.

Authors:  Anna Nogalska; Carla D'Agostino; W King Engel; Mafalda Cacciottolo; Shinichi Asada; Kazutoshi Mori; Valerie Askanas
Journal:  J Neuropathol Exp Neurol       Date:  2015-06       Impact factor: 3.685

2.  Clinical characteristics and molecular genetic analysis of Korean patients with GNE myopathy.

Authors:  Jae Eun Sim; Hyung-Jun Park; Ha Young Shin; Tai-Seung Nam; Seung Min Kim; Young-Chul Choi
Journal:  Yonsei Med J       Date:  2013-05-01       Impact factor: 2.759

3.  A Rare Case of Sporadic Inclusion Body Myositis (s-IBM).

Authors:  Sourya Acharya; Samarth Shukla; Pritum Kitey; Shameem Khan; S N Mahajan
Journal:  J Clin Diagn Res       Date:  2016-01-01

Review 4.  UDP-GlcNAc 2-Epimerase/ManNAc Kinase (GNE): A Master Regulator of Sialic Acid Synthesis.

Authors:  Stephan Hinderlich; Wenke Weidemann; Tal Yardeni; Rüdiger Horstkorte; Marjan Huizing
Journal:  Top Curr Chem       Date:  2015

5.  Aquaporin-4 expression in distal myopathy with rimmed vacuoles.

Authors:  Akihiko Hoshi; Teiji Yamamoto; Saeko Kikuchi; Tomoko Soeda; Keiko Shimizu; Yoshikazu Ugawa
Journal:  BMC Neurol       Date:  2012-04-27       Impact factor: 2.474

6.  Rimmed vacuoles in Becker muscular dystrophy have similar features with inclusion myopathies.

Authors:  Kazunari Momma; Satoru Noguchi; May Christine V Malicdan; Yukiko K Hayashi; Narihiro Minami; Keiko Kamakura; Ikuya Nonaka; Ichizo Nishino
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

7.  Nationwide patient registry for GNE myopathy in Japan.

Authors:  Madoka Mori-Yoshimura; Yukiko K Hayashi; Naohiro Yonemoto; Harumasa Nakamura; Miho Murata; Shin'ichi Takeda; Ichizo Nishino; En Kimura
Journal:  Orphanet J Rare Dis       Date:  2014-10-11       Impact factor: 4.123

8.  Pregnancy in GNE myopathy patients: a nationwide repository survey in Japan.

Authors:  Wakako Yoshioka; Naoyuki Miyasaka; Ryo Okubo; Reiko Shimizu; Yuji Takahashi; Yuriko Oda; Ichizo Nishino; Harumasa Nakamura; Madoka Mori-Yoshimura
Journal:  Orphanet J Rare Dis       Date:  2020-09-11       Impact factor: 4.123

9.  A case report: identification of a novel exon 1 deletion mutation in the GNE gene in a Chinese patient with GNE myopathy.

Authors:  Jing Miao; Xiao-Jing Wei; Xu Wang; Xiang Yin; Xue-Fan Yu
Journal:  Medicine (Baltimore)       Date:  2020-10-09       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.